Published: 7 September 2017
Publications
Recent Approvals of Medicines Containing a New Active Ingredient
Prescriber Update 38(3): 44
September 2017
For period 16 April 2017 to 15 July 2017
Trade Name (active ingredient)* | Dose form and strength | Therapeutic area |
---|---|---|
Akynzeo (netupitant/palonosetron)† | Combination capsule 300 mg/0.5 mg | Chemotherapy-induced nausea and vomiting |
Ibrance (palbociclib) | Capsule 75 mg, 100 mg and 125 mg | Hormone-receptor positive, HER2-negative, advanced breast cancer |
Idelvion (albutrepenonacog alfa) | Powder for injection 250 IU, 500 IU, 1000 IU and 2000 IU | Haemophilia B |
Nucala (mepolizumab) | Powder for injection 100 mg/mL | Eosinophilic asthma |
Ranexa (ranolazine) | Modified release tablet 375 mg, 500 mg and 750 mg | Angina |
* New active ingredient shown in bold type
† Not available
The data sheets for currently marketed prescription medicines are published on the Medsafe website (www.medsafe.govt.nz/profs/Medicines/infoSearch.asp).